FDA grants priority review to Roche ’s polatuzumab vedotin in previously treated aggressive lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (Source: Roche Investor Update)
Source: Roche Investor Update - February 19, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s polatuzumab vedotin in previously treated aggressive lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (Source: Roche Media News)
Source: Roche Media News - February 19, 2019 Category: Pharmaceuticals Source Type: news

Maintenance Rituximab Post Bendamustine/Rituximab in FL
Is the continuation of maintenance rituximab beneficial post bendamustine plus rituximab treatment in FL Patients? (Source: CancerNetwork)
Source: CancerNetwork - January 22, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

AbbVie Presents New Data from Phase 3 MURANO Trial of ...
- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1] - Of the 130 patients who completed rituximab plus the 24-month fixed duration of venetoclax and remained off therapy for a median of 9.9 months, the estimated PFS rate at six and 12 months were 92 percent and 87 percent, respectively[1] -...This story is related to the following:Pharmaceuticals (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - December 5, 2018 Category: Medical Devices Source Type: news

Ibrutinib Alone for Older Patients With Untreated CLL Ibrutinib Alone for Older Patients With Untreated CLL
Ibrutinib alone and ibrutinib with rituximab were both superior to the bendamustine – rituximab combination for older patients with chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib/BR Combo Improves Survival in CLL
Long-term data from the phase III HELIOS trial indicates ibrutinib plus bendamustine and rituximab improve survival outcomes in CLL patients. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a s... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Venetoclax, Bendamustine, and Rituximab in Refractory NHL Venetoclax, Bendamustine, and Rituximab in Refractory NHL
A study has established the safety profile of the anti-apoptotic B-cell leukemia/lymphoma-2 protein venetoclax in combination with bendamustine and rituximab.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Updated GADOLIN Study Shows Survival Benefit in Indolent NHL Updated GADOLIN Study Shows Survival Benefit in Indolent NHL
An updated analysis of the GADOLIN study confirms the PFS benefit of obinutuzumab and bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Venetoclax/Obinutuzumab Effective in CLL
A study shows bendamustine followed by venetoclax and obinutuzumab was active in treatment-naive or relapsed/refractory CLL. (Source: CancerNetwork)
Source: CancerNetwork - September 5, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Venetoclax and Rituximab: New Standard of Care in CLL? Venetoclax and Rituximab: New Standard of Care in CLL?
The new combination of venetoclax and rituximab was superior to the standard-of-care combination of bendamustine and rituximab in the treatment of relapsed/refractory CLL.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Media News)
Source: Roche Media News - December 12, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2017 Category: Pharmaceuticals Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2017 Category: Pharmaceuticals Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - December 10, 2017 Category: Pharmaceuticals Source Type: news

Roche, AbbVie leukemia drug superior to older medicine in study
(Reuters) - Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Media News)
Source: Roche Media News - September 18, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

Triplet Combo Active in Lenalidomide-Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Treanda (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2017 Category: Drugs & Pharmacology Source Type: news

MorphoSys initiates Phase III trial of MOR208 and bendamustine for DLBCL
German biotechnology firm MorphoSys has initiated patient enrolment for the Phase III part of the Phase II/III B-MIND clinical trial of MOR208 and bendamustine combination to treat diffuse large B-cell lymphoma (DLBCL). (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2017 Category: Pharmaceuticals Source Type: news

Bendamustine Toxicity in FL Raises Eyebrows -- and Questions Bendamustine Toxicity in FL Raises Eyebrows -- and Questions
Results from the GALLIUM study in follicular lymphoma (FL) showed that fatal toxicity was higher with bendamustine compared with other regimens. What does this mean for clinical practice?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Bendeka (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2016 Category: Drugs & Pharmacology Source Type: news

Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - June 16, 2016 Category: Pharmaceuticals Source Type: news

Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Media News)
Source: Roche Media News - June 16, 2016 Category: Pharmaceuticals Source Type: news

Response to 'Cure for Mantle Cell Lymphoma Within Reach'Response to 'Cure for Mantle Cell Lymphoma Within Reach'
Researchers not involved in the current research contest the characterization of bendamustine and rituximab as a "salvage" therapy, among other concerns. Letters to the Editor (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Rituximab Plus Bendamustine vs Standard Therapy for CLLRituximab Plus Bendamustine vs Standard Therapy for CLL
For patients with chronic lymphocytic leukemia (CLL), the combination of rituximab plus bendamustine was less effective than standard therapy, but it was also less toxic. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 27, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

First-line rituximab + bendamustine cost effective in advanced FL
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2016 Category: Drugs & Pharmacology Source Type: news

CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance as a new treatment for people with follicular lymphoma who did not respond to, or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Media News)
Source: Roche Media News - April 29, 2016 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance as a new treatment for people with follicular lymphoma who did not respond to, or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - April 29, 2016 Category: Pharmaceuticals Source Type: news

The U.S. Throws Out $3 Billion In Cancer Drugs Every Year
(Reuters Health) - U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and require doses adjusted based on the patient’s body size. Often, the packages contain much more medicine than patients need, and the leftovers wind up in the trash. Even when much of the medicine goes in the garbage, patients pay for the ...
Source: Science - The Huffington Post - March 28, 2016 Category: Science Source Type: news

FDA approves Roche’s Gazyva to treat follicular lymphoma
The US Food and Drug Administration (FDA) has granted approval for Roche's approved Gazyva (obinutuzumab) plus bendamustine chemotherapy, followed by Gazyva alone as a new treatment for people with follicular lymphoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 1, 2016 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® (rituximab)-containing regimen, or had their follicular lymphoma return after such treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 29, 2016 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® (rituximab)-containing regimen, or had their follicular lymphoma return after such treatment. (Source: Roche Media News)
Source: Roche Media News - February 29, 2016 Category: Pharmaceuticals Source Type: news

FDA Okay for Obinutuzumab for Follicular LymphomaFDA Okay for Obinutuzumab for Follicular Lymphoma
The FDA has approved obinutuzumab to be used in combination with bendamustine as second-line treatment for follicular lymphoma. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 26, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
South San Francisco, CA -- February 26, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) plus bendamustine chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2016 Category: Drugs & Pharmacology Source Type: news

Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer. EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment. MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and v...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news

Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP ™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP & trade; biomarker for Mundipharma EDO & rsquo;s lead compound EDO-S101 for the treatment of cancer. EDO-S101 is a first in class fusion molecule that combines two drugs & #39; mechanism of action in the cancer cell in order to increase the effect of treatment. MPI & #39;s specific DRP & trade; multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the c...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news

Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP ™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer.EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment.MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and vorinos...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news

Bendeka (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 16, 2015 Category: Drugs & Pharmacology Source Type: news

Teva, Eagle Cancer Drug Gets FDA Nod
FDA has approved BENDEKA injection -- a liquid, low-volume, 10-minute infusion formulation of bendamustine (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 9, 2015 Category: Pharmaceuticals Source Type: news

Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'
In chronic lymphocytic leukemia, idelalisib combined with bendamustine and rituximab improved progression-free and overall survival compared with the standard two-drug combination. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 9, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Teva gets FDA approval for cancer drug
(Reuters) - Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2015 Category: Consumer Health News Tags: healthNews Source Type: news